Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Salar Hemmati"'
Autor:
Fatemeh Dabagh, Fatemeh Khalili, Aynaz Zarghampour, Salar Hemmati, Jalal Hanaee, Elaheh Rahimpour, Abolghasem Jouyban
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-12 (2024)
Abstract This study aimed to measure both the solubility and thermodynamics of salicylic acid in binary solvent mixtures of (2-propanol + ethylene glycol) and (2-propanol + propylene glycol) at different temperatures in the range of 293.2–313.2 K.
Externí odkaz:
https://doaj.org/article/40a6320bba5a4c889a9da84056482187
Autor:
Maryam Rafraf, Mahdiyeh Khadem Haghighian, Roghayeh Molani-Gol, Salar Hemmati, Mohammad Asghari Jafarabadi
Publikováno v:
Nutrition and Metabolic Insights, Vol 17 (2024)
Objective: Osteoarthritis (OA) as a common musculoskeletal disorder is the main cause of disability in the world. The present study aimed to evaluate the effects of pomegranate peel extract (PPE) on some inflammatory markers and matrix maloproteinase
Externí odkaz:
https://doaj.org/article/f5d520dd15404f739fea8effccb379f1
Autor:
Elina Armani, Parisa Jafari, Salar Hemmati, Elaheh Rahimpour, Mohammad Barzegar-Jalali, Abolghasem Jouyban
Publikováno v:
BMC Chemistry, Vol 17, Iss 1, Pp 1-12 (2023)
Abstract Mesalazine (5-ASA) is a medication utilized to treat inflammatory bowel diseases involving ulcerative colitis and Crohn’s disease. Mesalazine has fewer side effects but the low solubility and bioavailability of it is responsible for its de
Externí odkaz:
https://doaj.org/article/a22045a3c1144430977a3c3211aeea93
Publikováno v:
Advanced Pharmaceutical Bulletin, Vol 13, Iss 3, Pp 592-600 (2023)
Purpose: Teduglutide is the first and only FDA-approved drug for long-term treatment of short bowel syndrome (SBS). The current study aimed to present an approach for production of teduglutide using recombinant DNA technology. Methods: The coding gen
Externí odkaz:
https://doaj.org/article/55ae25c3538d41cbb7d4172498f7ec70
Autor:
Reza Ravandi, Saeed Zeinali Heris, Salar Hemmati, Marziyeh Aghazadeh, Soodabeh Davaran, Nima Abdyazdani
Publikováno v:
Heliyon, Vol 10, Iss 6, Pp e27734- (2024)
The aim of this study was to improve the self-healing properties of dental nanocomposite using nanoparticles of TiO2 and chitosan. We evaluated flexural and compressive strength, crack-healing, and self-healing lifespan after 3 months of water aging.
Externí odkaz:
https://doaj.org/article/83898a0dfc3449ebad2667cb48e041f9
Publikováno v:
Biosensors, Vol 13, Iss 5, p 547 (2023)
Imatinib mesylate, an anticancer drug, is prescribed to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. A hybrid nanocomposite of N,S-doped carbon dots/carbon nanotube-poly(amidoamine) dendrimer (N,S-CDs/CNTD) was successfully
Externí odkaz:
https://doaj.org/article/8113e2de7d7c463a9f7044f230c820d3
Publikováno v:
Nutrition Journal, Vol 19, Iss 1, Pp 1-13 (2020)
Abstract Background There is a promising outlook regarding the potential effect of spinach-derived thylakoids in the management of obesity and its associated metabolic disturbances. This research aimed to evaluate the effects of spinach-derived thyla
Externí odkaz:
https://doaj.org/article/72dd00a344184a34823072aa5cb524d3
Autor:
Somayeh Mahdinloo, Seyed Hossein Kiaie, Ala Amiri, Salar Hemmati, Hadi Valizadeh, Parvin Zakeri-Milani
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 10, Iss 7, Pp 1279-1293 (2020)
Liver fibrosis results from chronic damages together with an accumulation of extracellular matrix, and no specific medical therapy is approved for that until now. Due to liver metabolic capacity for drugs, the fragility of drugs, and the presence of
Externí odkaz:
https://doaj.org/article/22d181362e234b8f93ab5c381d6eae55
Autor:
Aziz Shahrisa, Salar Hemmati
Publikováno v:
Iranian Journal of Chemistry & Chemical Engineering, Vol 15, Iss 2, Pp 76-80 (1996)
Synthesis of 4-(N,N- dimethylamino)-3-aryl-3-butene-2-one, ethyl-5-aryl-4-oxo-4H-pyran-2-carboxylate, ethyl-5-aryl-4-pyridones-2-carboxylate and 5-aryl-3-cyano-5-methyl-2-pyridones (aryl=3-thienyl, 2-furyl) are described.
Externí odkaz:
https://doaj.org/article/70ab8f12597e46bab5d395dde0df75d8
Publikováno v:
Journal of Pharmaceutical Sciences. 111:2758-2764
Mesalazine is a low-permeable and low-soluble drug, which makes it a class IV drug in the Biopharmaceutics Classification System. Hence, its solubilization can be helpful for various stages of formulation development. The purpose of this study was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c1d05c0d34a136f887f7743b5de223
https://doi.org/10.1016/j.xphs.2022.07.018
https://doi.org/10.1016/j.xphs.2022.07.018